GP Mental Health Bites Archives

February 25, 2023

Application of Intranasal Esketamine (Spravato®) in Clinical Practice – Interview Highlights with Prof Ian Hickie and A/Prof Liz Scott
In this month...
READ MORE
January 30, 2023

Referral Pathway for Esketamine (SPRAVATO Nasal Spray) in Treatment-Resistant Depression?
In this video we guide you through the development and documentation of a Personal Recovery Plan for a patient with treatment-...
READ MORE
December 28, 2022

Completing a GP Mental Health Treatment Plan in Treatment-Resistant Depression (TRD)-Part 1
In this video, Dr Sanil Rege takes you through the completion of the relevant sections of the GP mental health treatment plan (GPMHTP) with a focus on d...
READ MORE
November 21, 2022

Intranasal Esketamine Clinical Data – Implications for Patients and Clinicians
In this video, Dr Sanil Rege, consultant psychiatrist reviews the key clinical data for intranasal esketamine in the managemen...
READ MORE
November 7, 2022

Diagnostic Evaluation in Severe Anxiety Disorder – A Structured Approach
Approximately 50% of patients with a ...
READ MORE
October 23, 2022

Practical Application of Motivational Interviewing in Patients with Schizophrenia
In this video, Dr Sanil Rege reviews the practice and principles of Motivational Interviewing (MI). We will discuss: Four key proces...
READ MORE
September 14, 2022

Neurobiology of Depression and Psychopharmacology of Esketamine – A Novel Rapid-acting Antidepressant
In this video, Dr Sanil Rege reviews the ...
READ MORE
August 23, 2022

Paliperidone 3-monthly and 6-monthly Long Acting Injectables in Schizophrenia – Key Points
Welcome to the Fifteenth Edition of the GP Mental Health Bites! This month’s edition of GP Mental Health Bites informs on what you, as a GP, ne...
READ MORE
July 18, 2022

Navigating a Case of Treatment-Resistant Depression (TRD) in Clinical Practice
The term treatment-resistant depression (TRD) is problematic because it has been associated with a narrow focus on pharmacotherapeutic non-response and ...
READ MORE
June 20, 2022

Long-Acting Injectable Antipsychotics (LAIs) – What do the RANZCP Guidelines Say?
Long-acting injectable antipsychotics (LAIs) are an effective treatment option in schizophrenia. However, they are often viewed negatively by clinicia...
READ MORE

Application of Intranasal Esketamine (Spravato®) in Clinical Practice – Interview Highlights with Prof Ian Hickie and A/Prof Liz Scott

Referral Pathway for Esketamine (SPRAVATO Nasal Spray) in Treatment-Resistant Depression?

Completing a GP Mental Health Treatment Plan in Treatment-Resistant Depression (TRD)-Part 1

Intranasal Esketamine Clinical Data – Implications for Patients and Clinicians

Diagnostic Evaluation in Severe Anxiety Disorder – A Structured Approach

Practical Application of Motivational Interviewing in Patients with Schizophrenia

Neurobiology of Depression and Psychopharmacology of Esketamine – A Novel Rapid-acting Antidepressant

Paliperidone 3-monthly and 6-monthly Long Acting Injectables in Schizophrenia – Key Points

Navigating a Case of Treatment-Resistant Depression (TRD) in Clinical Practice

Long-Acting Injectable Antipsychotics (LAIs) – What do the RANZCP Guidelines Say?